Yongliang Yang

Caigang Liu

eLife Assessment
This study presents a valuable finding on mutations in ZNF217, ZNF703, and ZNF750 through 23 breast cancer samples alongside matched normal tissues in Kenyan breast cancer patients. The evidence supporting the claims of the authors is solid, yet the analysis of the manuscript lacks methodological transparency, statistical detail, and sufficient comparison with existing large-scale datasets. The work will be of interest to medical biologists and scientists working in the field of breast cancer.

anonymous

Reviewer #1 (Public review):
Summary:
This manuscript investigates mutations and expression patterns of zinc finger proteins in Kenyan breast cancer patients.
Strengths:
Whole-exome sequencing and RNA-seq were performed on 23 breast cancer samples alongside matched normal tissues in Kenyan breast cancer patients. The authors identified mutations in ZNF217, ZNF703, and ZNF750.
Weaknesses:
(1) Research scope:
The results primarily focus on mutations in ZNF217, ZNF703, and ZNF750, with limited correlation analyses between mutations and gene expression. The rationale for focusing only on these genes is unclear. Given the availability of large breast cancer cohorts such as TCGA and METABRIC, the authors should compare their mutation profiles with these datasets. Beyond European and U.S. cohorts, sequencing data from multiple countries, including a recent Nigerian breast cancer study (doi: 10.1038/s41467-021-27079-w), should also be considered. Since whole-exome sequencing was performed, it is unclear why only four genes were highlighted and why comparisons to previous literature were not included.
(2) Language and Style Issues:
Several statements read somewhat 'unnaturally', and I strongly recommend proofreading.
(3) Methods and Data Analysis Details:
The methods section is vague, with general descriptions rather than specific details of data processing and analysis. The authors should provide:
(a) Parameters used for trimming, mapping, and variant calling (rather than referencing another paper such as Tang et al. 2023).
(b) Statistical methods for somatic mutation/SNP detection.
(c) Details of RNA purification and RNA-seq library preparation.
Without these details, the reproducibility of the study is limited.
(4) Data Reporting:
This study has the potential to provide a valuable resource for the field. However, data-sharing plans are unclear. The authors should:
(a) deposit sequencing data in a public repository.
(b) provide supplementary tables listing all detected mutations and all differentially expressed genes (DEGs).
(c) clarify whether raw or adjusted p-values were used for DEG analysis.
(d) perform DEG analyses stratified by breast cancer subtypes, since differential expression was observed by HER2 status, and some zinc finger proteins are known to be enriched in luminal subtypes.
(5) Mutation Analysis:
Visualizations of mutation distribution across protein domains would greatly strengthen interpretation. Comparing mutation distribution and frequency with published datasets would also contextualize the findings.

Reviewer #2 (Public review):
Summary:
This work integrated the mutational landscape and expression profile of ZNF molecules in 23 Kenyan women with breast cancer.
Strengths:
The mutation landscape of ZNF217, ZNF703, and ZNF750 was comprehensively studied and correlated with tumor stage and HER2 status to highlight the clinical significance.
Weaknesses:
The current study design is relatively simple, and there is a limited cohort size, which is relatively small to reach significant findings. Thus, sample size enrichment, along with more analytic work, is needed.
Targeted exploration of the ZNF family without emphasizing the reason or clinical significance hinders the overall significance of the entire work.

Reviewer #3 (Public review):
Summary:
The authors aimed to define the somatic mutational landscape and transcriptomic expression of the ZNF217, ZNF703, and ZNF750 genes in breast cancers from Kenyan women and to investigate associations with clinicopathological features like HER2 status and cancer stage. They employed whole-exome and RNA-sequencing on 23 paired tumor-normal samples to achieve this.
Strengths:
(1) A major strength is the focus on a Kenyan cohort, addressing a critical gap in genomic studies of breast cancer, which are predominantly based on European or Asian populations.
(2) The integration of DNA- and RNA-level data from the same patients provides a comprehensive view, linking genetic alterations to expression changes.
Weaknesses:
(1) The small cohort size (n=23) significantly limits the statistical power to detect associations between genetic features and clinical subgroups (e.g., HER2 status, stage), rendering the negative findings inconclusive.
(2) The study is primarily descriptive. While it effectively catalogs mutations and expression changes, it does not include functional experiments to validate the biological impact of the identified alterations.

Mutational and Expression Profile of ZNF217, ZNF750, ZNF703 Zinc Finger Genes in Kenya Women diagnosed with Breast Cancer

Figures and data

Be the first to read new articles from eLife